Real‐world analysis of haemophilia patients in China: A single centre's experience-Reference-Cited by-同舟云学术

Real‐world analysis of haemophilia patients in China: A single centre's experience

Published:2020-05-20 Issue:4 Volume:26 Page:584-590
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Song Xuewen¹^ORCID,Liu Wei¹,Xue Feng¹,Zhong Jia¹²,Yang Yifan¹,Liu Yi¹,Xie Jipan²,Wu Eric²,Zhang Lei¹,Shi Jun¹,Yang Renchi¹^ORCID

Affiliation:

1. State Key Laboratory of Experimental Hematology Tianjin Laboratory of Blood Disease Gene Therapy CAMS Key Laboratory of Gene Therapy for Blood Diseases National Clinical Research Center for Hematological Disorders Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China

2. Analysis Group, Inc. Beijing China

Funder

Chinese Academy of Medical Sciences

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14029

Reference14 articles.

1. Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017);Thrombosis, Hemostasis Group HSoCMA, Hemophilia Treatment Center Collaborative Network of C;Zhonghua Xue Ye Xue Za Zhi,2017

2. Prophylaxis in haemophilia should be life‐long;Makris M;Blood Transfus,2012

3. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China

4. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males

5. The prevalence of hemophilia in mainland China: a systematic review and meta‐analysis;Qu Y;Southeast Asian J Trop Med Public Health,2014

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status of treatment and disease burden of a cohort of hemophilia B in China;Frontiers in Public Health;2024-01-24

3. Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China;Heliyon;2023-03

4. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting;BMC Medical Research Methodology;2022-08-05

5. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A;Haemophilia;2022-07-08